Cat. #160389
Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)
Cat. #: 160389
Sub-type: Nanoparticle
Availability: Please enquire for quantities and pricing
Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Claus Feldmann
Institute: Karlsruhe Institute of Technology
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: Tin Tungstate Nanoparticles Beta-SnWO4 small molecule (tool compound)
- Cancer: Breast cancer;Skin cancer
- Cancers detailed: Breast cancer;Colon;Esophageal;Gastric;Skin cancer
- Research fields: Cancer;Metabolism
- Tool sub type: Nanoparticle
- Primary target: Near-surface tumours
- Description: Tin Tungstate nanoparticles act as photosensitizers for photodynamic tumor therapy of near-surface tumors via reiterated 5 min blue-light LED illumination.
- Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.
- Additional notes: "The nanoparticulate inorganic photosensitizer β-SnWO4 is suggested for photodynamic therapy (PDT) of near-surface tumors via reiterated 5 min blue-light LED illumination. β-SnWO4 nanoparticles are obtained via water-based synthesis and comprise excellent colloidal stability under physiological conditions and high biocompatibility at low material complexity. Antitumor and antimetastatic effects were investigated with a spontaneously metastasizing (4T1 cells) orthotopic breast cancer BALB/c mouse model. Besides protamine-functionalized β-SnWO4 (23 mg/kg of body weight, in PBS buffer), chemotherapeutic doxorubicin was used as positive control (2.5 mg/kg of body weight, in PBS buffer) and physiological saline (DPBS) as a negative control. After 21 days, treatment with β-SnWO4 resulted in a clearly inhibited growth of the primary tumor (all tumor volumes below 3 cm3) as compared to the doxorubicin and DPBS control groups (volumes up to 6 cm3). Histological evaluations of lymph nodes and lungs as well as the volume of ipsilateral lymph nodes show a remarkable antimetastatic effect being similar to chemotherapeutic doxorubicin butîaccording to blood countsîat significantly reduced side effects. On the basis of low material complexity, high cytotoxicity under blue-light LED illumination at low dark and long-term toxicity, β-SnWO4 can be an interesting addition to PDT and the treatment of near-surface tumors, including skin cancer, esophageal/gastric/colon tumors as well as certain types of breast cancer." From Seidl et al 2016, ACS Nano, 10, 3149â3157.
Handling
- Shipping conditions: Dry Ice
Target Details
- Primary target: Near-surface tumours
Application Details
- Application: Used to treat tumours in BALB/C mice orthotopically inoculated with the 4T1 breast cancer cell line. Reduced lymph node metastases.Killed 4T1 cells in vitro.
References
- Seidl et al. 2016. ACS Nano. 10(3):3149-57. PMID: 26894966.
- Ungelenk et al. 2014. Chem Commun (Camb). 50(50):6600-3. PMID: 24824575.
- Ungelenk et al. 2012. Chem Commun (Camb). 48(63):7838-40. PMID: 22735092.